-
-
-
-
-
-
-
Truist Securities on Scholar Rock (SRRK): today's Roche news 'neutral to positive'
-
-
-
-
-
-
-
Scholar Rock (SRRK) PT Raised to $55 at Truist Securities
-
-
-
-
-
-
-
UBS Starts Scholar Rock (SRRK) at Buy
-
-
-
-
-
-
-
Scholar Rock stock falls after FDA flags issues at manufacturing facility
-
-
-
-
-
-
-
FDA rejects Scholar Rock's apitegromab application due to facility issues
-
-
-
-
-
-
-
Raymond James Reiterates Strong Buy Rating on Scholar Rock (SRRK)
-
-
-
-
-
-
-
Jefferies: 'We highlight multiple de-risked or commercial-stage names that we think have promising M&A potential'
-
408,970 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

